Esperion Therapeutics (NASDAQ:ESPR) focuses on the research, development, and commercialization of innovative lipid management products to improve cardiovascular health. Its primary projects revolve around the development of therapies aimed at reducing bad cholesterol levels, with a notable emphasis on bempedoic acid and its combinations as a new option for patients struggling with cardiovascular diseases. Esperion aims to address the significant unmet medical needs in the cardiovascular space, aspiring to reduce the global burden of cardiovascular diseases through its groundbreaking therapies. The company's objectives are geared towards improving the accessibility and effectiveness of cholesterol management options for patients and healthcare providers, ultimately striving to lead the advancement in cardiovascular health solutions on a global scale.